- Sativex - GW Pharmaceuticals' treatment for spasticity in Multiple Sclerosis - has been rescheduled in the UK from Schedule 1 under the Misuse of Drugs Act to Schedule 4, Part 1.

The move follows a recommendation to the Home Office by the Advisory Council on Misuse of Drugs (ACMD), which determined that Sativex has a low potential for abuse and low risk of diversion.

At 8:14am: [LON:GWP] GW Pharmaceuticals share price was +8.88p at 79.25p

Story provided by